healthcare

With volatility persisting investors may want to consider this defensive sector, supported by valuations and long-term growth drivers.

Numerous economic and geopolitical risks continue to remain on the horizon and are keeping many people up at night, not just investors.

It's been a wild ride for ResMed over the past couple of years and while there might be further volatility, things are back on track

Advances in healthcare are one of the greatest advantages of the times we live in and it's only getting more exciting (and profitable).

Murdoch sat down with James McDonald, PM at Pengana. We discuss key sectors, including healthcare, titanium, Japan, resources and more.

Plus, fund managers outline the key trends shaping the sector.

The healthcare sector is benefiting from rapid innovation, fuelled by a significant jump in COVID-led funding.

AI has enormous potential to improve healthcare delivery across the globe, and some practical applications could benefit investors.

With the healthcare sector in a deep and prolonged downturn, valuations of public and private R&D stage companies are very attractive.

Markets were more subdued in April after the strong start to the year. The S&P/ASX 200 Accumulation Index was down 2.9% and the S&P/ASX Small Ordinaries Accumulation...

Early-stage healthcare investment is not for the faint-hearted (or under-researched). No one could accuse Hashan De Silva of either.

Pulsed Field Ablation is the most exciting technology to come to market in many years, and offers great potential returns for the winners

Drug development pipelines are the lifeblood of the pharmaceutical industry. It is crucial for investors to understand milestones like FDA approvals and the impact of...

Telix Pharmaceuticals has just reported its first year of positive operating cashflow... helping it to achieve NPAT.

The rapid pace of change in biotechnology is creating a golden age of innovation - and three experts share what they are watching.

CSL has delivered bumper returns once again in its half-year report but suffered a major setback this week.

There are two parts of the market we believe are setting up for strong returns in 2024: Small caps and Healthcare.

The medtech landscape is rife with fast growing companies typically operating in oligopolistic industry structures that drive profitability.

The collapse of China chatter seems overcooked. The China A-share market now looks like a screaming buy, so I list my Crazy-Eight top picks.

Below is a summary of the topics we covered on Nucleus Investment Insights this month. See the links for more information.